Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients' Upper and Lower Airways after IV-Antibiotic Therapy

Mediators Inflamm. 2015:2015:626530. doi: 10.1155/2015/626530. Epub 2015 Jun 21.

Abstract

Background: In cystic fibrosis (CF) the upper (UAW) and lower airways (LAW) are reservoirs for pathogens like Pseudomonas aeruginosa. The consecutive hosts' release of proteolytic enzymes contributes to inflammation and progressive pulmonary destruction. Objectives were to assess dynamics of protease : antiprotease ratios and pathogens in CF-UAW and LAW sampled by nasal lavage (NL) and sputum before and after intravenous- (IV-) antibiotic therapy.

Methods: From 19 IV-antibiotic courses of 17 CF patients NL (10 mL/nostril) and sputum were collected before and after treatment. Microbiological colonization and concentrations of NE/SLPI/CTSS (ELISA) and MMP-9/TIMP-1 (multiplex bead array) were determined. Additionally, changes of sinonasal symptoms were assessed (SNOT-20).

Results: IV-antibiotic treatment had more pronounced effects on inflammatory markers in LAW, whereas trends to decrease were also found in UAW. Ratios of MMP-9/TIMP-1 were higher in sputum, and ratios of NE/SLPI were higher in NL. Remarkably, NE/SLPI ratio was 10-fold higher in NL compared to healthy controls. SNOT-20 scores decreased significantly during therapy (P = 0.001).

Conclusion: For the first time, changes in microbiological patterns in UAW and LAW after IV-antibiotic treatments were assessed, together with changes of protease/antiprotease imbalances. Delayed responses of proteases and antiproteases to IV-antibiotic therapy were found in UAW compared to LAW.

MeSH terms

  • Adolescent
  • Adult
  • Anti-Bacterial Agents / administration & dosage*
  • Case-Control Studies
  • Cathepsins / analysis
  • Child
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / enzymology
  • Cystic Fibrosis / microbiology
  • Female
  • Humans
  • Injections, Intravenous
  • Leukocyte Elastase / analysis
  • Male
  • Matrix Metalloproteinase 9 / analysis
  • Middle Aged
  • Prospective Studies
  • Pseudomonas aeruginosa / isolation & purification*
  • Secretory Leukocyte Peptidase Inhibitor / analysis
  • Sputum / microbiology
  • Tissue Inhibitor of Metalloproteinase-1 / analysis*

Substances

  • Anti-Bacterial Agents
  • SLPI protein, human
  • Secretory Leukocyte Peptidase Inhibitor
  • Tissue Inhibitor of Metalloproteinase-1
  • Cathepsins
  • Leukocyte Elastase
  • cathepsin S
  • Matrix Metalloproteinase 9